PMID- 35777333
OWN - NLM
STAT- MEDLINE
DCOM- 20220803
LR  - 20220803
IS  - 1532-2688 (Electronic)
IS  - 1059-1311 (Linking)
VI  - 100
DP  - 2022 Aug
TI  - Perampanel for the treatment of patients with myoclonic seizures in clinical 
      practice: Evidence from the PERMIT study.
PG  - 56-66
LID - S1059-1311(22)00142-X [pii]
LID - 10.1016/j.seizure.2022.06.008 [doi]
AB  - PURPOSE: To investigate the effectiveness, safety and tolerability of perampanel 
      (PER) in treating myoclonic seizures in clinical practice, using data from the 
      PERaMpanel pooled analysIs of effecTiveness and tolerability (PERMIT) study. 
      METHODS: PERMIT was a pooled analysis of 44 real-world studies from 17 countries, 
      in which patients with focal and generalised epilepsy were treated with PER. This 
      post-hoc analysis included patients with myoclonic seizures at baseline. 
      Retention and effectiveness were assessed after 3, 6, and 12 months; 
      effectiveness was additionally assessed at the last visit (last observation 
      carried forward). Effectiveness assessments included responder rate (>/=50% seizure 
      frequency reduction from baseline) and seizure freedom rate (no seizures since at 
      least the prior visit). Safety and tolerability were assessed by evaluating 
      adverse events (AEs) and discontinuation due to AEs. RESULTS: 156 patients had 
      myoclonic seizures (59.0% female; mean age, 32.1 years; idiopathic generalised 
      epilepsy, 89.1%; Juvenile Myoclonic Epilepsy, 63.1%; monthly median myoclonic 
      seizure frequency [interquartile range], 1.7 [1.0-10.0]; mean [standard 
      deviation] prior antiseizure medications, 2.9 [2.6]). Retention was assessed for 
      133 patients (mean time, 12.1 months), effectiveness for 142, and 
      safety/tolerability for 156. Responder and seizure freedom rates were, 
      respectively, 89.5% and 68.8% at 12 months, and 85.9% and 63.4% at the last 
      visit. Incidence of AEs was 46.8%, the most frequent being dizziness/vertigo 
      (19.2%), irritability (18.6%) and somnolence (9.6%). AEs led to discontinuation 
      of 14.0% of patients over 12 months. CONCLUSION: PER was associated with 
      reduction in myoclonic seizure frequency in patients with myoclonic seizures 
      treated in everyday clinical practice.
CI  - Copyright (c) 2022. Published by Elsevier Ltd.
FAU - D'Souza, Wendyl
AU  - D'Souza W
AD  - Department of Medicine, St Vincent's Hospital Melbourne, The University of 
      Melbourne, PO Box 2900, Fitzroy, Victoria 3065, Australia.. Electronic address: 
      wendyl@unimelb.edu.au.
FAU - Alsaadi, Taoufik
AU  - Alsaadi T
AD  - American Center for Psychiatry and Neurology, United Arab Emirates; Khalifa 
      University, Abu Dhabi, United Arab Emirates.
FAU - Montoya, Javier
AU  - Montoya J
AD  - Epilepsy Unit, Hospital Clinic Barcelona, Barcelona, Spain.
FAU - Carreno, Mar
AU  - Carreno M
AD  - Hospital Clinic Barcelona, Barcelona, Spain.
FAU - Di Bonaventura, Carlo
AU  - Di Bonaventura C
AD  - Epilepsy Unit, Department of Human Neurosciences, "Sapienza" University of Rome, 
      Rome, Italy.
FAU - Mohanraj, Rajiv
AU  - Mohanraj R
AD  - Manchester Centre for Clinical Neurosciences, Salford Royal Hospital, UK.
FAU - Yamamoto, Takamichi
AU  - Yamamoto T
AD  - Comprehensive Epilepsy Center, Seirei Hamamatsu General Hospital, Shizuoka, 
      Japan.
FAU - McMurray, Rob
AU  - McMurray R
AD  - Eisai Europe Limited, Hatfield, Hertfordshire, UK.
FAU - Shastri, Oliver
AU  - Shastri O
AD  - Eisai Europe Limited, Hatfield, Hertfordshire, UK.
FAU - Villanueva, Vicente
AU  - Villanueva V
AD  - Refractory Epilepsy Unit, Hospital Universitario y Politecnico La Fe, Valencia, 
      Spain.
CN  - PERMIT study group
LA  - eng
PT  - Journal Article
DEP - 20220615
PL  - England
TA  - Seizure
JT  - Seizure
JID - 9306979
RN  - 0 (Anticonvulsants)
RN  - 0 (Nitriles)
RN  - 0 (Pyridones)
RN  - H821664NPK (perampanel)
SB  - IM
MH  - Adult
MH  - *Anticonvulsants/adverse effects
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - *Myoclonic Epilepsy, Juvenile/drug therapy
MH  - Nitriles
MH  - Pyridones/adverse effects
MH  - Seizures/chemically induced/drug therapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Antiseizure medication
OT  - Clinical practice
OT  - Generalised epilepsy
OT  - Myoclonic seizures
OT  - Perampanel
OT  - Real world
EDAT- 2022/07/02 06:00
MHDA- 2022/08/04 06:00
CRDT- 2022/07/01 18:32
PHST- 2022/04/07 00:00 [received]
PHST- 2022/06/10 00:00 [revised]
PHST- 2022/06/14 00:00 [accepted]
PHST- 2022/07/02 06:00 [pubmed]
PHST- 2022/08/04 06:00 [medline]
PHST- 2022/07/01 18:32 [entrez]
AID - S1059-1311(22)00142-X [pii]
AID - 10.1016/j.seizure.2022.06.008 [doi]
PST - ppublish
SO  - Seizure. 2022 Aug;100:56-66. doi: 10.1016/j.seizure.2022.06.008. Epub 2022 Jun 
      15.